[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
October 15, 1997

Treatment of Verruca Vulgaris With Topical Cidofovir

Author Affiliations

Dallas Ft Worth Medical Center Grand Prairie, Tex
University of Oklahoma Health Sciences Center Oklahoma City
University of Texas Southwestern Medical Center Dallas

JAMA. 1997;278(15):1236. doi:10.1001/jama.1997.03550150040032

To the Editor.  —Cidofovir is a nucleotide analog of deoxycytidine monophosphate and has antiviral activity against a broad range of DNA viruses, including cytomegalovirus and herpesviruses.1-3 Topical cidofovir has been reported as a successful treatment for refractory condyloma acuminatum3 in human immunodeficiency virus infection and recurrent genital herpes.4 We report the use of topical cidofovir in 2 patients with verruca vulgaris resistant to repeated conventional therapies.

Report of Cases.  —An 8-year-old girl with no history of significant medical illness had been treated unsuccessfully with numerous conventional therapies (eg, electrodesiccation, topical cantharidin, topical tretinoin, oral cimetidine) for extensive (several hundred lesions), biopsy-proven verruca vulgaris of both lower extremities for 2 years. After obtaining informed consent, we initiated application of 3% topical cidofovir twice daily. Marked erythema and irritation without erosion or ulceration were evident by day 10, and therapy was halted. No systemic adverse effects were noted.